<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152966">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01795690</url>
  </required_header>
  <id_info>
    <org_study_id>iOM TAn</org_study_id>
    <nct_id>NCT01795690</nct_id>
  </id_info>
  <brief_title>Clinical Registry on Anemia-Therapy (TAn-Registry)</brief_title>
  <acronym>TAn-Registry</acronym>
  <official_title>Clinical Registry Describing Treatment Reality of Patients With Cancer-induced Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ASORS (Arbeitsgemeinschaft Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin der Deutschen Krebsgesellschaft)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vifor Pharma Deutschland GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to record information of routine treatment of anemia in
      cancer patients in Germany. An overview of the current treatment of anemia in German
      outpatient centers and hospitals will be provided. Primary outcome parameters, e.g.
      improvement in hemoglobin levels and changes in QoL, as well as patient characteristics of
      different treatments will be analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Documentation of therapies</measure>
    <time_frame>12 weeks per patient</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overview on the current routine treatment of anemia in cancer patients in Germany</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin levels and QoL</measure>
    <time_frame>12 weeks per patient</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy of different antianemic treatments is investigated by measuring increase of hemoglobin levels and QoL (FACT-An and FACT-GP).
Baseline in hemoglobin (before treatment) is compared with hemoglobin levels after treatment. Each patient is followed for a maximum of 12 weeks to obtain data about the course of the treatment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1018</enrollment>
  <condition>Anemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Practitioners specialized in oncology in Germany German outpatient centers an hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological verifiable tumor disease

          -  Hemoglobin level &lt; standard value

          -  Antianemic therapy

          -  Performance status 0 - 3 (Karnofsky-Index &gt;= 40%)

          -  Minimum age: 18 years

          -  Informed written consent

        Exclusion Criteria:

          -  hypersensitivity against antianemic therapies

          -  Myelodysplastic Syndrome

          -  experimental antianemic therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>iOMEDICO</name>
      <address>
        <city>Freiburg</city>
        <zip>79108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007 Jan;43(2):258-70. Epub 2006 Dec 19. Review.</citation>
    <PMID>17182241</PMID>
  </reference>
  <reference>
    <citation>Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008;13 Suppl 3:33-6. doi: 10.1634/theoncologist.13-S3-33.</citation>
    <PMID>18458123</PMID>
  </reference>
  <reference>
    <citation>Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004 Oct;40(15):2293-306.</citation>
    <PMID>15454256</PMID>
  </reference>
  <reference>
    <citation>Barrett-Lee PJ, Ludwig H, Birgegård G, Bokemeyer C, Gascón P, Kosmidis PA, Krzakowski M, Nortier JW, Kongable G, Schneider M, Schrijvers D, Van Belle SJ; European Cancer Anaemia Survey Advisory Board and Participanting Centers. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology. 2006;70(1):34-48. Epub 2006 Feb 21.</citation>
    <PMID>16493206</PMID>
  </reference>
  <reference>
    <citation>Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010 Jan 19;102(2):301-15. doi: 10.1038/sj.bjc.6605498. Epub 2010 Jan 5.</citation>
    <PMID>20051958</PMID>
  </reference>
  <reference>
    <citation>Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005033. Review.</citation>
    <PMID>16437512</PMID>
  </reference>
  <reference>
    <citation>Spivak JL, Gascón P, Ludwig H. Anemia management in oncology and hematology. Oncologist. 2009;14 Suppl 1:43-56. doi: 10.1634/theoncologist.2009-S1-43. Review.</citation>
    <PMID>19762516</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>October 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Cancer</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>FACT-An</keyword>
  <keyword>FACT-GP</keyword>
  <keyword>Erythropoiesis-Stimulating Agents (ESA)</keyword>
  <keyword>Epoetin</keyword>
  <keyword>Ferric Carboxymaltose</keyword>
  <keyword>Blood Transfusions</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hematinics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
